Virax Biolabs Group Ltd balance sheet

At the end of fiscal 2026, Virax Biolabs Group Ltd had total assets of $8.3m, total liabilities of $989,832 and shareholders' equity of $7.6m. It held $6.4m in cash against $0 of debt: net cash of $6.4m.

Balance sheet

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Virax Biolabs Group Ltd: balance sheet, annual
Fiscal year	2021Mar 2021	2022Mar 2022	2023Mar 2023	2024Mar 2024	2025Mar 2025	2026Mar 2026
Cash and equivalents	18	22	9,353	3,589	4,229	6,439
Inventory	21	21	0	60	95	0
Total current assets	40	49	9,634	4,380	4,894	6,829
Total assets	40	49	9,812	5,484	6,427	8,325
Total current liabilities	871	1,245	908	169	673	685
Total debt	—	0	0	0	0	0
Total liabilities	871	1,245	908	345	965	990
Shareholders' equity	−651	−975	9,126	5,367	5,696	7,577
Non-controlling interests and other (assets − liabilities − equity)	−181	−222	−222	−228	−234	−242
Net debt (negative = net cash)	−18	−22	−9,353	−3,589	−4,229	−6,439
Shares outstanding	—	—	—	—	—	—

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: LYEL vs VRAX CELZ vs VRAX AIM vs VRAX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Virax Biolabs Group Ltd's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Virax Biolabs Group Ltd.